This HTML5 document contains 24 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

PrefixNamespace IRI
dcthttp://purl.org/dc/terms/
covidprhttp://ns.inria.fr/covid19/property/
foafhttp://xmlns.com/foaf/0.1/
fabiohttp://purl.org/spar/fabio/
n7http://ns.inria.fr/covid19/b709cdc1b8ee8fbe8b44e27ddb2b0e321285067c#
dcehttp://purl.org/dc/elements/1.1/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
bibohttp://purl.org/ontology/bibo/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
covidhttp://ns.inria.fr/covid19/
n8https://doi.org/10.1007/
xsdhhttp://www.w3.org/2001/XMLSchema#
Subject Item
covid:b709cdc1b8ee8fbe8b44e27ddb2b0e321285067c
rdf:type
schema:ScholarlyArticle bibo:AcademicArticle fabio:ResearchPaper
rdfs:isDefinedBy
covid:dataset-1-2
dct:title
Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
dce:creator
Reilly, Joseph Jacobs, Micah Lombardi, David Cleveland, Kerry Bibiana Castaneda-Ruiz, · Friedman, ·
dct:source
PMC
dct:abstract
n7:abstract
dct:issued
2020-05-05
bibo:doi
10.1007/s40801-020-00191-x
bibo:pmid
32372280
dct:license
cc-by-nc
foaf:sha1
b709cdc1b8ee8fbe8b44e27ddb2b0e321285067c
schema:url
n8:s40801-020-00191-x
covidpr:hasTitle
n7:title
fabio:hasPubMedCentralId
PMC7223833
fabio:hasPubMedId
32372280
schema:publication
Drugs Real World Outcomes
covidpr:hasBody
n7:body_text